WeedOUT Ltd Overview
WeedOUT is an Israeli agricultural biotechnology developer. Its product is a species-specific biological herbicide that works through reproduction, not through plant toxicity. The method borrows the logic of the sterile insect technique, which has been used against flies and mosquitoes since the 1940s. The company:
-
grows male plants of a target weed;
-
harvests their pollen;
-
sterilises the pollen by irradiation;
-
releases it over infested fields.
The treated pollen fertilises female weed flowers but produces non-viable, aborted seed. This depletes the weed seedbank season after season. The first target is Palmer amaranth (Amaranthus palmeri), the most economically damaging herbicide-resistant weed in US cotton, soybean, corn and sugar beet. It is also a serious problem in Brazil and Argentina. WeedOUT positions the product as a complement to chemical programmes inside integrated weed management, not as a replacement. Its core value claim is that it attacks a complex reproductive process rather than a single enzyme pathway, which should make resistance harder to evolve. As of the latest public information, the company is pre-revenue and awaiting US EPA marketing approval.
What the company does
WeedOUT develops what it describes as the industry's first species-specific biological herbicide (AgFunder News, 2020). The production chain has four steps:
-
Male plants of the target weed species are grown in controlled net houses. Palmer amaranth produces fresh pollen daily (AgWeb).
-
The pollen is collected.
-
The pollen is irradiated so it is sterile but still able to fertilise.
-
Target weeds in the field are artificially pollinated with dispersing equipment, currently using a dry application (AgFunder 2020; AgWeb).
According to the company, its pollen has two key properties:
-
it competes successfully against naturally occurring weed pollen;
-
it still fertilises the ovule (Future Farming, 2024).
Co-founder Efrat Lidor Nili has told trade press that every seed formed after fertilisation with WeedOUT pollen is aborted (AgWeb). The company stresses that the pollen is exclusive to Palmer amaranth and does not affect row crops or other plants (AgWeb).
Company's own description
WeedOUT does not publish an annual report. In its February 2024 funding announcement, the company describes its technology as a novel, environmentally conscious way to sharply curb the spread of weeds that no longer respond to common chemical herbicides (Precision Farming Dealer, 2024). Startupim's owner-claimed profile adds three points:
-
the product is made with natural ingredients;
-
its aim is to reduce reliance on toxic herbicides and escalating doses;
-
it blocks the next generation of viable weed seeds through artificial pollination (Startupim raw profile).
Independent characterisation
WeedOUT is best described as a pre-commercial, single-asset biological crop-protection platform company. The platform claim rests on the idea that the sterile-pollen method can be repeated across other wind-pollinated, dioecious weeds. Palmer amaranth is a near-ideal first target for three reasons:
-
it is dioecious (separate male and female plants), so female flowers depend entirely on outside pollen;
-
it produces very large seed numbers per female plant, so cutting seed set has a compounding effect on the seedbank;
-
it has developed resistance to multiple herbicide modes of action.
The company is also developing formulations for other weed species (Produce Processing, 2024). It intends to extend first to other Amaranthus weeds (AgWeb); waterhemp (A. tuberculatus) is the logical next candidate, though the company has not publicly named it.
Mode of action. The product does not kill the treated plant. Management has acknowledged that a standing Palmer plant late in the season is probably already resistant. The treatment's job is to stop that plant from contributing viable seed (Farm Progress, 2020). The economic benefit is therefore multi-season seedbank reduction, not in-season yield protection. This has major consequences for how the product is sold, priced and demonstrated (see §10 and §22).
Business and revenue model
| Dimension | Characterisation | Basis |
|---|---|---|
| Revenue model | Expected product sales of treated pollen, possibly bundled with application services or equipment. No revenue disclosed. | Inferred from product description; no disclosure |
| Product vs service vs subscription vs licensing mix | Not publicly disclosed. Caplight lists the business model as B2B and the customer profile as "Hardware Sales" | Caplight |
| Value-chain position | Upstream crop-protection input developer, analogous to a biological active-ingredient registrant | Independent characterisation |
| Customer types | Commercial row-crop growers (cotton, soybean, corn, sugar beet); likely routed through ag retailers or distributors and strategic partners | Series A release (2024) |
| End-markets | US Southeast and Midwest row crops first; Brazil and Argentina named as Palmer markets | Global AgInvesting (2024) |
| Go-to-market | Not publicly disclosed. The lead investor's network of US farmers is cited as an asset | Series A release (2024) |
Strategy
Stated strategic themes (paraphrased from company communications)
-
A biological, non-chemical answer to herbicide resistance. The company targets weed reproduction rather than a single enzymatic pathway, which management argues makes resistance harder to evolve. Its reference point is that sterility techniques in insects have shown no resistance problems in about 80 years (Series A release, 2024).
-
Complement, not replace. Co-CEO Noivirt-Brik has framed the product as letting farmers integrate a biological approach with traditional methods (African Farming, 2024). This positions WeedOUT inside integrated weed management alongside herbicides, cover crops and harvest weed-seed control.
-
Ecosystem compatibility. Because only weeds are treated with pollen, the method is designed to avoid threats to the food crop (Series A release, 2024).
-
Platform expansion. New formulations for other weed species, beginning with other Amaranthus species (Produce Processing 2024; AgWeb).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Detail | Status |
|---|---|---|
| US field-trial expansion | Georgia, Nebraska and other regions; run with key opinion leaders in weed control | Announced Feb 2024; outcomes not published |
| EPA marketing approval | Application for the Palmer amaranth product | Submitted by Feb 2024; approval not confirmed publicly |
| Manufacturing scale-up | Upscaling pollen manufacturing, storage and application | Ongoing (AgWeb) |
| Pipeline formulations | Other weed species | In development |
Public disclosure in this window is minimal. The announced initiatives date from the February 2024 round and are presumed to be ongoing:
Medium-term financial targets or guidance: not publicly disclosed.
ESG commitments: not formally published. The product itself is positioned as a green, herbicide-reducing solution.
Product Portfolio
| Product / programme | Description | Key specifications / capabilities | Target customer | Status / year | Pricing |
|---|---|---|---|---|---|
Palmer amaranth sterile-pollen bioherbicide (commercial brand name not publicly disclosed) | Irradiated A. palmeri pollen applied by artificial pollination so female plants set aborted, non-viable seed | Species-specific to Palmer and does not affect row crops or other plants (AgWeb). Dry application; pollen is very light (AgWeb). Company states 100% abortion of seed formed after WeedOUT fertilisation (AgWeb). Competes with wild pollen (Future Farming 2024) | US cotton, soybean, corn and sugar beet growers; later Brazil and Argentina | EPA marketing-approval application submitted by Feb 2024. No public confirmation of approval found as of Oct 2026 | — |
Pollen production system (internal capability) | Net-house cultivation of male plants, daily pollen collection, irradiation, storage | Scale-up of manufacturing, storage and application under way (AgWeb) | Internal | Ongoing | — |
Pollen dispersal / application equipment | Field dispersal equipment for artificial pollination | Caplight's "Hardware Sales" tag suggests possible equipment revenue. Unconfirmed | Growers / applicators | Development | — |
Next-species formulations | New formulations for other weed species, extending first to other Amaranthus weeds | — | Row-crop growers | Development (2024 release) | — |
“—” = not publicly disclosed.
Financial Narrative
Income statement
WeedOUT publishes no financial statements. The company is pre-commercial, so revenue is expected to be nil or immaterial. Even so, the revenue figure is not disclosed and is left blank rather than set to zero.
Revenue CAGR: not computable.
Ratios
ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are all not publicly disclosed or not computable. No underlying statements exist in the public domain.
Equity funding history — the only quantified financial data available
Commentary. Total disclosed capital is about USD 11–14M over roughly eight years. That is modest for a company seeking a novel EPA registration and building a biological manufacturing chain.
-
The roughly 3.3-year gap between the 2020 and 2024 rounds points to capital-efficient, trial-driven development, helped by Israeli grant support.
-
The 2024 round was earmarked for US trial expansion and launch preparation. Assuming a typical burn for an Israeli agbio company of this stage (not disclosed), the company would probably need further capital in 2026–2027 to fund commercial launch and manufacturing scale-up.
-
No public record of a post-2024 round was found as of October 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (Independent Characterisation) Overview
| Segment (independent characterisation) | Contents |
|---|---|
Sterile-pollen bioherbicides — revenue (USD Mn; not publicly disclosed) | Palmer amaranth product; pipeline formulations for other weeds |
Balance Sheet
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
Disclosed equity raised (USD Mn; Startupim round data) | 0.25 | 3.0 | 0 | 0 | 0 | 8.1 |
Round | Date | Amount (USD) | Lead | Other participants | Source | — |
Competition-linked investment | c.2019 | — | Radicle Growth (Radicle Challenge Israel prize) | — | Farm Progress (2020) | — |
Seed | Oct 2019 | 0.25M | — | — | Startupim | — |
Series A (first close) | Early 2020 | — | Syngenta Ventures | — | AgFunder News (2020) | — |
Series A | Nov 2020 | 3.0M | Not disclosed (likely the Syngenta-led round) | — | Startupim | — |
Series A (extension) | 20 Feb 2024 | 8.1M | Fulcrum Global Capital | Bunge Ventures; Clay Capital (formerly VisVires New Protein) | Global AgInvesting (2024); Caplight | — |
Non-dilutive grants | Various | — | Israel Innovation Authority; EU Horizon 2020 | — | AgFunder (2020); Future Farming (2024) | — |
“—” = not publicly disclosed.
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable (unlisted) |
Private valuation | Not publicly disclosed (Caplight secondary pricing paywalled) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | Not publicly disclosed; financing believed to be equity plus grants |
Metric | FY2019 |
Cumulative disclosed equity raised (USD Mn; Startupim round data) | 0.25 |
Analyst Conclusions
Management guidance
None published. The stated near-term objectives as of February 2024 were:
-
expand US field trials;
-
obtain EPA approval;
-
launch the inaugural Palmer amaranth product.
Consensus expectations
None (no coverage).
Bull case
-
Resistance-proof mode of action at the right moment. Over-the-top dicamba registrations were vacated in 2024 (DTN), and growers face 263 resistant species globally (Global AgInvesting). A biological that attacks reproduction rather than an enzyme has a defensible, differentiated position.
-
Strategic backing gives a distribution route. Syngenta Ventures led the first institutional round, and Bunge and Fulcrum's US farmer network joined later. That provides credible paths to licensing, distribution or acquisition without WeedOUT building a full sales force.
-
Platform optionality. Once the pollen production, irradiation and dispersal chain is validated on Palmer, extending to waterhemp and other Amaranthus species could add major US Midwest acreage at incremental R&D cost.
Bear case
-
Hard-to-sell benefit. The product does not kill the treated plant (Farm Progress, 2020), and payback comes from seedbank decline over several seasons. That is difficult to demonstrate and price against herbicides that show visible in-season kill.
-
Scientific and scale risk. Syngenta's own managing director flagged that pollen may underperform the insect analogue (AgFunder, 2020). Pollen production depends on daily harvest from living plants (AgWeb). Efficacy and unit economics at commercial acreage remain unproven publicly.
-
Time and capital. EPA approval had not been publicly confirmed more than 2.5 years after filing. No new financing has been disclosed since Feb 2024. Total disclosed funding is about USD 11–14M, and BASF is bringing new chemistry around 2027 (Iowa Farm Bureau, 2026). The company risks a funding squeeze before commercial proof.
Key catalysts and monitorables (next 12 months)
-
EPA registration decision for the Palmer amaranth product.
-
A new financing round (size, lead, any strategic participation, especially from Syngenta or Bayer).
-
Publication of multi-season US field data (Georgia, Nebraska), ideally peer-reviewed or university-extension-validated.
-
Commercial partnership, distribution or licensing agreement.
-
Clarity on the December 2025 officeholder change.
-
Announcement of a second target species.
-
Regulatory filings in Brazil or Argentina.
Concluding analyst verdict
WeedOUT is a scientifically original, strategically well-sponsored, but still pre-commercial and thinly disclosed agricultural biotechnology venture. Its central insight is to turn Palmer amaranth's dependence on outside pollen into a weakness. That insight is elegant and matches a real, worsening agronomic crisis. Palmer can erase most of a crop's yield, and the chemical toolbox keeps shrinking, as the 2024 court vacatur of over-the-top dicamba registrations showed. Against that backdrop, a non-toxic, species-specific mode of action that should be robust to resistance is precisely what growers and regulators say they want. Investor quality is above average for its stage: Syngenta Ventures, Bunge Ventures and Fulcrum Global Capital give the company both validation and plausible exit or distribution routes.
The investment case nevertheless hinges on three unresolved questions that public information cannot yet answer:
Field performance: Does sterile pollen outcompete wild pollen enough, at realistic application rates, to cut seed return meaningfully in heavily infested commercial fields?
Manufacturing economics: Can a living, daily-harvested, irradiated input be produced, stored and delivered at a cost growers will pay for a benefit that appears only over several seasons?
Regulatory and financial runway: Will the company obtain EPA approval and raise follow-on capital before competing chemistries and investor patience run out?
It does not imply failure; the company remains registered and active. But it means the risk profile has not been visibly de-risked in over two and a half years. Verdict: high-potential, high-risk, binary early-stage asset. Its EPA decision and next financing round are the defining near-term events.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure |
|---|---|---|
Efrat Lidor Nili, PhD | Co-founder and co-CEO | 2016–present |
Orly Noivirt-Brik, PhD | Co-founder and co-CEO | 2016–present |
Competitive Landscape
Key Competitors
| # | Competitor | Category | Approach | Relative positioning vs WeedOUT |
|---|---|---|---|---|
| 1 | Bayer Crop Science | Chemical / traits incumbent | Herbicides and herbicide-tolerant traits | Scale incumbent. Over-the-top dicamba setback (2024) highlights a vulnerability |
| 2 | Syngenta Group | Chemical incumbent | Herbicide portfolio | Also a WeedOUT investor: competitor and potential partner |
| 3 | BASF Agricultural Solutions | Chemical incumbent | New all-in-one herbicide targeting 2027 availability | Direct substitute in the Palmer programme budget |
| 4 | Corteva Agriscience | Chemical / traits incumbent | Herbicides and tolerant traits | Scale incumbent |
| 5 | FMC Corporation | Chemical incumbent | Pre-emergent herbicides and new modes of action | Incumbent with new-chemistry pipeline |
| 6 | Moa Technology (UK) | Novel herbicide discovery start-up | New herbicide modes of action | Competing "new mode of action" narrative |
| 7 | Micropep Technologies (France) | Biological start-up | Peptide-based crop protection, including weeds | Peer in biological herbicides |
| 8 | Harpe Bio (US) | Bioherbicide start-up | Natural-product herbicides | Peer in biological herbicides |
| 9 | Carbon Robotics (US) | Mechanical / robotic | Laser weeding | Non-chemical alternative, mainly specialty crops |
| 10 | Greeneye Technology (Israel) | Precision spraying | AI-driven targeted herbicide application | Reduces herbicide volume; does not solve resistance |
| 11 | Harvest weed-seed control (e.g., Redekop Seed Control Unit, Harrington Seed Destructor) | Mechanical seedbank control | Destroys weed seed at harvest | Closest functional analogue. Also attacks the seedbank |
Key Competitors by Company
| Company | Revenue |
|---|---|
WeedOUT | Not publicly disclosed (pre-revenue) |
Bayer Crop Science | Not compiled in this research |
Syngenta Group | Not compiled in this research |
BASF Agricultural Solutions | Not compiled in this research |
Recent Developments
The verifiable items, plus the most recent pre-window anchors for context, are shown below.



